Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is up over 16% today on news of the company’s initiation of phase-II trials for its lead drug candidate KRN23, which is a monoclonal antibody for X-linked Hypophosphatemia (XLH). Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) stock performance was 14.30% in last session and finished the day at $48.67. Traded volume was 435,645.00million shares in the last session and the average volume of the stock remained 175.92K shares. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) insider ownership is 2.90%.

Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced positive topline clinical trial results from a Phase 2a synovial fluid PK study of FX006, which demonstrated, for the first time, that a single intra-articular (IA) injection of FX006 can provide therapeutic concentrations of drug in joint fluid for at least 12 weeks. FX006 is Flexion’s novel, non-opioid, sustained-release, IA formulation of TCA. Flexion Therapeutics Inc (NASDAQ:FLXN) rose 15.76 percent to $14.91 Wednesday on volume of 164,970.00million shares. The intra-day range of the stock was $12.76 to $15.14. Flexion Therapeutics Inc (NASDAQ:FLXN) has a market capitalization of $232.95million.

Receptos Inc (NASDAQ:RCPT) last released its earnings data on Monday, May 12th. The company reported ($1.01) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.84) by $0.17. The company had revenue of $1.40 million for the quarter, compared to the consensus estimate of $0.49 million. Analysts expect that Receptos will post $-4.19 EPS for the current fiscal year. Receptos Inc (NASDAQ:RCPT)’s stock on June 18, 2014 reported a increase of 6.52% to the closing price of $40.99. Its fifty two weeks range is $15.21 -$55.00. The total market capitalization recorded $908.72million. The overall volume in the last trading session was 1.28million shares. In its share capital, RCPT has 22.17million outstanding shares.

Acorda Therapeutics Inc (NASDAQ:ACOR) on June 18 announced the pricing of a public offering of $300 million principal amount of convertible senior notes due 2021 (the “Notes”). The Notes will bear interest at an annual rate of 1.75% and will mature on June 15, 2021, unless earlier converted, purchased or redeemed. Acorda granted the underwriter an option to purchase up to an additional $45 million principal amount of Notes to cover over-allotments, if any. The Notes will be convertible prior to December 15, 2020 only under certain circumstances and during certain periods, and will be convertible thereafter regardless of those circumstances. On Wednesday, shares of Acorda Therapeutics Inc (NASDAQ:ACOR) advanced 7.75% to close the day at $34.61. Company return on investment (ROI) is 4.00% and its monthly performance is recorded as 11.83%. Acorda Therapeutics Inc (NASDAQ:ACOR) quarterly revenue growth is -12.22%.

Aratana Therapeutics Inc (NASDAQ:PETX) Insider Julia A. Stephanus unloaded 8,000 shares of Aratana Therapeutics stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $13.90, for a total transaction of $111,200.00. Following the sale, the insider now directly owns 121,967 shares of the company’s stock, valued at approximately $1,695,341. Aratana Therapeutics Inc (NASDAQ:PETX) stock performance was 5.65% in last session and finished the day at $15.72. Traded volume was 300,796.00million shares in the last session and the average volume of the stock remained 218.84K shares. Aratana Therapeutics Inc (NASDAQ:PETX) insider ownership is 4.80%.